Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis.

MRI McDonald criteria cerebrospinal fluid clinically isolated syndrome multiple sclerosis oligoclonal bands

Journal

Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899

Informations de publication

Date de publication:
2019
Historique:
received: 03 01 2019
accepted: 14 02 2019
entrez: 2 4 2019
pubmed: 2 4 2019
medline: 2 4 2019
Statut: epublish

Résumé

Multiple sclerosis is a chronic immune mediated demyelinating disease leading to neurological disabilities that need to be diagnosed and treated early. Guidelines on multiple sclerosis diagnosis and monitoring experienced comprehensive changes over the last decades. The first McDonald criteria published in 2001 emphasized the importance of MR imaging but also recognized the role of cerebrospinal fluid diagnostics. The demonstration of an intrathecal immunoglobulin G synthesis is a well-established additional component and has a long tradition in the diagnosis of relapsing-remitting multiple sclerosis. However, the role of cerebrospinal fluid for diagnostic purposes was rather diminished in each revision of the McDonald criteria. In the latest revision of the McDonald criteria of 2017, the detection of an intrathecal immunoglobulin G synthesis as oligoclonal bands experienced a revival. Patients with the first clinical event suggesting multiple sclerosis who fulfill the criteria for dissemination in space can be diagnosed with relapsing-remitting multiple sclerosis when oligoclonal bands in cerebrospinal fluid are detected. The diagnostic sensitivity of these novel criteria with a focus on dissemination in time and oligoclonal bands as a substitute for dissemination in time was published in different cohorts in the last year and is of special interest in this review. Recently published data show that by applying the 2017 McDonald criteria, multiple sclerosis can be diagnosed more frequently at the time of first clinical event as compared to the 2010 McDonald criteria. The main effect was due to the implementation of oligoclonal bands as a substitute for dissemination in time. However, careful differential diagnosis is essential in patients with atypical clinical manifestations to avoid misdiagnoses.

Identifiants

pubmed: 30930829
doi: 10.3389/fneur.2019.00188
pmc: PMC6428717
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

188

Références

AJNR Am J Neuroradiol. 2000 Apr;21(4):702-6
pubmed: 10782781
Ann Neurol. 2001 Jul;50(1):121-7
pubmed: 11456302
Ann Neurol. 2001 Sep;50(3):389-400
pubmed: 11558796
Mult Scler. 2001 Dec;7(6):359-63
pubmed: 11795456
Ann Neurol. 2002 Jul;52(1):47-53
pubmed: 12112046
Mult Scler. 2003 Feb;9(1):39-43
pubmed: 12617267
Neurology. 2003 Apr 8;60(7):1163-6
pubmed: 12682325
Ann Biol Clin (Paris). 2003 Sep-Oct;61(5):563-9
pubmed: 14671754
Lancet Neurol. 2005 Jun;4(6):341-8
pubmed: 15907738
Arch Neurol. 2005 Jun;62(6):865-70
pubmed: 15956157
J Neurol Neurosurg Psychiatry. 2006 Jul;77(7):830-3
pubmed: 16043456
Ann Neurol. 2005 Dec;58(6):840-6
pubmed: 16283615
Neurology. 2006 Feb 28;66(4):576-8
pubmed: 16505315
Neurology. 2006 Oct 10;67(7):1242-9
pubmed: 16914693
J Neurol. 2008 Apr;255(4):480-7
pubmed: 18004635
Lancet Neurol. 2008 Sep;7(9):852-8
pubmed: 18703007
Mult Scler. 2008 Nov;14(9):1157-74
pubmed: 18805839
Lancet Neurol. 2008 Dec;7(12):1091-8
pubmed: 18851928
Mult Scler. 2009 Apr;15(4):472-8
pubmed: 19153171
J Neurol Sci. 2009 Jul 15;282(1-2):12-20
pubmed: 19249061
J Neuroimmunol. 2010 Feb 26;219(1-2):1-7
pubmed: 19782408
Lancet. 2009 Oct 31;374(9700):1503-11
pubmed: 19815268
Neurology. 2010 Feb 2;74(5):427-34
pubmed: 20054006
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Lancet Neurol. 2012 Feb;11(2):157-69
pubmed: 22265211
Mult Scler. 2013 Jul;19(8):1101-5
pubmed: 23380650
Nat Rev Neurol. 2013 May;9(5):267-76
pubmed: 23528543
J Neurol Sci. 2013 Dec 15;335(1-2):124-30
pubmed: 24071064
Autoimmun Rev. 2014 Apr-May;13(4-5):518-24
pubmed: 24424194
J Autoimmun. 2014 Feb-Mar;48-49:134-42
pubmed: 24524923
Mult Scler. 2015 Jul;21(8):1013-24
pubmed: 25680984
Fortschr Neurol Psychiatr. 2015 Feb;83(2):109-22
pubmed: 25723775
Brain. 2015 Jul;138(Pt 7):1863-74
pubmed: 25902415
Neurology. 2016 Aug 16;87(7):680-3
pubmed: 27421541
Neurology. 2016 Sep 27;87(13):1368-74
pubmed: 27566747
Int J Mol Sci. 2016 Sep 21;17(9):null
pubmed: 27657060
J Neurol. 2016 Dec;263(12):2499-2504
pubmed: 27730374
Eur Neurol. 2017;77(1-2):91-102
pubmed: 27997917
BMC Infect Dis. 2017 Jan 21;17(1):90
pubmed: 28109263
Int J Mol Sci. 2017 Sep 27;18(10):null
pubmed: 28953254
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Ann Neurol. 2018 Feb;83(2):283-294
pubmed: 29328521
Brain. 2018 Apr 1;141(4):1075-1084
pubmed: 29462277
Mult Scler. 2018 Apr 1;:1352458518770088
pubmed: 29648501
Mult Scler. 2018 Nov;24(13):1786-1787
pubmed: 29762077
Lancet Neurol. 2018 Jun;17(6):498
pubmed: 29778358
Mult Scler. 2018 Jul 25;:1352458518790702
pubmed: 30043667
Mult Scler Relat Disord. 2018 Oct;25:99-103
pubmed: 30059896
JAMA Neurol. 2018 Nov 1;75(11):1392-1398
pubmed: 30083703
J Neurol. 2018 Nov;265(11):2684-2687
pubmed: 30196327
Eur J Neurol. 2019 Mar;26(3):540-545
pubmed: 30362206
Neurology. 2019 Jan 1;92(1):26-33
pubmed: 30381369
Int J Mol Sci. 2018 Nov 29;19(12):null
pubmed: 30501024
Mult Scler Relat Disord. 2019 Apr;29:23-25
pubmed: 30658260
Ann Neurol. 1983 Mar;13(3):227-31
pubmed: 6847134
Neurology. 1995 Sep;45(9):1663-70
pubmed: 7675224
J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):897-902
pubmed: 8057110
J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):27-30
pubmed: 8558146
J Neurol Neurosurg Psychiatry. 1996 May;60(5):572-5
pubmed: 8778266
Brain. 1997 Nov;120 ( Pt 11):2059-69
pubmed: 9397021

Auteurs

Philipp Schwenkenbecher (P)

Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany.

Ulrich Wurster (U)

Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany.

Franz Felix Konen (FF)

Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany.

Stefan Gingele (S)

Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany.

Kurt-Wolfram Sühs (KW)

Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany.

Mike P Wattjes (MP)

Department of Diagnostic and Interventional Neuroradiology, Hannover Medical School, Hannover, Germany.

Martin Stangel (M)

Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany.

Thomas Skripuletz (T)

Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany.

Classifications MeSH